+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones



Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones



European Journal of Immunology 12(5): 406-412



Mouse mastocytoma P815 tumor cell variants that express new individual antigens were subjected to immunoselection in vitro with specific cytolytic T lymphocyte (CTL) clones. From 1 variant (P35) a number of resistant clones were isolated after a single-step selection. These immunoselected clones (P35.iscA-) proved to have acquired a stable and complete resistance to lysis by the selecting CTL, but remained sensitive to lysis by a CTL clone that recognizes a common P815 antigen. When these P35.iscA- clones were used to stimulate in vitro spleen cells from mice immunized with variant P35, the cytolytic activity was significantly higher on P35 and P35.iscA- targets than on the original P815 clone (P1). This indicated that P35.iscA- cells, which had lost a P35-specific determinant (P35B). CTL clones directed against the residual P35B determinant were then isolated. When P35 cells were submitted to selection with anti-P35B CTL, resistant clones (P35.iscB-) were obtained that were still lysed by anti-P35A and anti-P815 CTL clones. Tum- variant P35 therefore carries at least 2 specific determinants that can be lost independently. These results show the possibility of using selection with CTL clones to separate different components of complex cell surface antigens. The correlation between antigen expression and tumorigenicity was also examined. Antigen-loss P35.iscA- clones were found to be more tumorigenic than variant P35 which has a greatly reduced tumorigenic capacity compared to the original P815 tumor. The P35 determinant that was no longer expressed by the P35.iscA- clones apparently is recognized on the original P35 tum- variant as a tumor rejection antigen.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 043333055

Download citation: RISBibTeXText

PMID: 6178608

DOI: 10.1002/eji.1830120509


Related references

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens. European Journal of Immunology 12(11): 905-908, 1982

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids. Somatic Cell Genetics 9(3): 345-357, 1983

Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics 26(3): 178-187, 1987

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. European Journal of Immunology 12(5): 401-406, 1982

Immunogenic variants obtained by mutagenesis of mouse Lewis lung carcinoma. Recognition of variant-specific antigens by cytolytic T lymphocytes. European Journal of Cancer and Clinical Oncology 18(9): 867-874, 1982

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. Journal of Experimental Medicine 152(5): 1175-1183, 1980

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Ii. T lymphocyte-mediated cytolysis. Journal of Experimental Medicine 152(5): 1184-1193, 1980

Immunogenic variants obtained by mutagenesis of mouse masto cytoma p 815 6. occasional escape from host rejection due to antigen loss secondary variants. International Journal of Cancer 31(1): 119-124, 1983

Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815. European Journal of Cancer and Clinical Oncology 19(11): 1529-1537, 1983

Immunogenic variants obtained by mutagenesis by mouse masto cytoma p 815 7. dominant expression of variant antigens in somatic cell hybrids. Somatic Cell Genetics 9(3): 345-358, 1983

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. Journal of Experimental Medicine 157(3): 1040-1052, 1983

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proceedings of the National Academy of Sciences of the United States of America 85(7): 2274-2278, 1988

Dissection of new antigens expressed on immunogenic variants of masto cytoma p 815 that were obtained by mutagenesis. Immunobiology 163(2-4): 144-145, 1982

H-2 antigen variants in a cultured heterozygous mouse leukemia cell line. VI. Rate of emergence of the hemizygous variants and evidence that the variants preexist the selection. Immunogenetics 10(5): 411-422, 1980

Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. Journal of Experimental Medicine 157(6): 1992-2001, 1983